Study Comparing Dry Powder Ivy Extract Syrup Prospan and N-Acetylcysteine for Treating Stable COPD in Adults 40 and Older

What this Trial Is About

Chronic Obstructive Pulmonary Disease COPD is a leading cause of death worldwide affecting over 300 million people, often leading to frequent exacerbations that worsen health and quality of life. This research evaluates the efficacy and safety of two mucolytic treatments, dry powder Ivy Extract Syrup Prospan and N-Acetylcysteine NAC, in managing COPD symptoms and preventing exacerbations. The study aims to compare cough symptoms, quality of life, lung function, and patient satisfaction between these treatments over 30 days. Participants with stable COPD will be randomly assigned to receive either Syrup Prospan 7.5 mL twice daily or N-Acetylcysteine 600 mg twice daily for one month. The study is open-label and will run from May 2024 to November 2026. Both groups will be monitored for adherence, side effects, and treatment satisfaction. The trial aims to recruit around 100 participants, equally divided between the two treatments. Participants will undergo baseline evaluations including spirometry, COPD assessment tests, and questionnaires on cough and quality of life before starting treatment. Follow-up visits will occur on Day 15 and Day 30 to assess compliance and repeat tests. Researchers will measure cough severity using the Cough and Sputum Assessment Questionnaire, quality of life with the McGill COPD Questionnaire, and lung function by spirometry. Safety and treatment satisfaction will also be monitored throughout the 30-day period.

Efficacy & Safety of Dry Powder Ivy Extract (Syrup Prospan) Versus NAC Among COPD Patients